Ongoing standardized verification of the accuracy of blood glucose meters systems for self-monitoring post-launch is important clinically and helps confirm appropriate performance of subsequently released lots of strips. 1 In addition, publication of such studies is increasingly becoming a component of informed comparative purchasing decisions. ISO 15197:2013, 2 for which mandatory compliance is recommended for SMBG systems by 2016, 3 has tighter accuracy requirements than ISO 15197:2003, 4 and outlines current minimum accuracy standards necessary in Europe for CE marking.
demonstrates performance in relation to the minimum accuracy requirements of ISO 15197:2013 where for each of the 3 lots of strips at least 95% of results must fall within ±15 mg/dl of the comparison measurement results at blood glucose concentrations <100 mg/dl and within ±15% at concentrations ≥100 mg/dl. The standard also requires that at least 99% of individual results fall within consensus error grid zones A and B (5) when clinical accuracy is evaluated with 3 test strip lots. The relative bias according to Bland and Altman (6) ranged from -5.43% to -4.00% and the mean absolute relative difference from 6.24% to 6.99%.
In conclusion, this study demonstrates that the TD-4277 SMBG system fulfils and exceeds the minimum analytical and clinical accuracy requirement of ISO 15197:2013. 
